New therapeutic agents for chronic hepatitis B
Summary The treatment goal for chronic hepatitis B is true eradication of the hepatitis B virus, but this is rarely achieved with first-line treatment regimens because of an inability to disrupt covalently closed circular DNA and an inadequate host immune response. Therefore, new antiviral agents ar...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2016-02, Vol.16 (2), p.e10-e21 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e21 |
|---|---|
| container_issue | 2 |
| container_start_page | e10 |
| container_title | The Lancet infectious diseases |
| container_volume | 16 |
| creator | Brahmania, Mayur, MD Feld, Jordan, MD Arif, Ambreen, MD Janssen, Harry L A, Prof |
| description | Summary The treatment goal for chronic hepatitis B is true eradication of the hepatitis B virus, but this is rarely achieved with first-line treatment regimens because of an inability to disrupt covalently closed circular DNA and an inadequate host immune response. Therefore, new antiviral agents are needed to target various stages of the hepatitis B virus lifecycle and modulation of the immune system. This Review provides a summary of available regimens with their strengths and limitations, and highlights future therapeutic strategies to target the virus and host immune response. These new agents can hopefully lead to a finite duration of treatment, and provide a functional and durable cure for chronic hepatitis B infection. |
| doi_str_mv | 10.1016/S1473-3099(15)00436-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1765108112</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309915004363</els_id><sourcerecordid>1765108112</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-173f3405fb5e9469bbabb8bc622ad9ab0df36ba274db9373c0074a317d8e0d063</originalsourceid><addsrcrecordid>eNqFkE2P0zAQhi3Eii2FnwCKxKUcUsbxV3IB7VbArlTBAThbtjOhLmlS7ATUf7_5KIu0l_VlrNEzrz0PIa8orClQ-e4b5YqlDIpiRcVbAM5kyp6QxdDmKedCPZ3uM3JJnse4B6CKAn9GLjOpCiELtiDrL_g36XYYzBH7zrvE_MSmi0nVhsTtQtsMrR0eTec7H5PrF-SiMnXEl-e6JD8-ffy-uUm3Xz_fbq62qRNSdilVrGIcRGUFFlwW1hprc-tklpmyMBbKiklrMsVLWzDFHIDihlFV5gglSLYkqzn3GNrfPcZOH3x0WNemwbaPmiopKOSUZgP65gG6b_vQDL8bqYyLnA1nScRMudDGGLDSx-APJpw0BT0K1ZNQPdrSVOhJqB7nXp_Te3vA8n7qn8EB-DADOOj44zHo6Dw2Dksf0HW6bP2jT7x_kOBqP3g39S88Yfy_jY6ZhjlkzKBiSmDsDp_Zl7Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1762458333</pqid></control><display><type>article</type><title>New therapeutic agents for chronic hepatitis B</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Brahmania, Mayur, MD ; Feld, Jordan, MD ; Arif, Ambreen, MD ; Janssen, Harry L A, Prof</creator><creatorcontrib>Brahmania, Mayur, MD ; Feld, Jordan, MD ; Arif, Ambreen, MD ; Janssen, Harry L A, Prof</creatorcontrib><description>Summary The treatment goal for chronic hepatitis B is true eradication of the hepatitis B virus, but this is rarely achieved with first-line treatment regimens because of an inability to disrupt covalently closed circular DNA and an inadequate host immune response. Therefore, new antiviral agents are needed to target various stages of the hepatitis B virus lifecycle and modulation of the immune system. This Review provides a summary of available regimens with their strengths and limitations, and highlights future therapeutic strategies to target the virus and host immune response. These new agents can hopefully lead to a finite duration of treatment, and provide a functional and durable cure for chronic hepatitis B infection.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(15)00436-3</identifier><identifier>PMID: 26795693</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Antiviral agents ; Antiviral Agents - therapeutic use ; Deoxyribonucleic acid ; DNA ; Genomes ; Heparan sulfate ; Hepatitis ; Hepatitis B ; Hepatitis B virus - drug effects ; Hepatitis B, Chronic - drug therapy ; Humans ; Immune response ; Immune system ; Infectious Disease ; Infectious diseases ; Inflammation ; Interferon ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Mutation ; Polypeptides ; Proteins ; Virus Replication - drug effects</subject><ispartof>The Lancet infectious diseases, 2016-02, Vol.16 (2), p.e10-e21</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Feb 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-173f3405fb5e9469bbabb8bc622ad9ab0df36ba274db9373c0074a317d8e0d063</citedby><cites>FETCH-LOGICAL-c566t-173f3405fb5e9469bbabb8bc622ad9ab0df36ba274db9373c0074a317d8e0d063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309915004363$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26795693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brahmania, Mayur, MD</creatorcontrib><creatorcontrib>Feld, Jordan, MD</creatorcontrib><creatorcontrib>Arif, Ambreen, MD</creatorcontrib><creatorcontrib>Janssen, Harry L A, Prof</creatorcontrib><title>New therapeutic agents for chronic hepatitis B</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Summary The treatment goal for chronic hepatitis B is true eradication of the hepatitis B virus, but this is rarely achieved with first-line treatment regimens because of an inability to disrupt covalently closed circular DNA and an inadequate host immune response. Therefore, new antiviral agents are needed to target various stages of the hepatitis B virus lifecycle and modulation of the immune system. This Review provides a summary of available regimens with their strengths and limitations, and highlights future therapeutic strategies to target the virus and host immune response. These new agents can hopefully lead to a finite duration of treatment, and provide a functional and durable cure for chronic hepatitis B infection.</description><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Genomes</subject><subject>Heparan sulfate</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Inflammation</subject><subject>Interferon</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Mutation</subject><subject>Polypeptides</subject><subject>Proteins</subject><subject>Virus Replication - drug effects</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkE2P0zAQhi3Eii2FnwCKxKUcUsbxV3IB7VbArlTBAThbtjOhLmlS7ATUf7_5KIu0l_VlrNEzrz0PIa8orClQ-e4b5YqlDIpiRcVbAM5kyp6QxdDmKedCPZ3uM3JJnse4B6CKAn9GLjOpCiELtiDrL_g36XYYzBH7zrvE_MSmi0nVhsTtQtsMrR0eTec7H5PrF-SiMnXEl-e6JD8-ffy-uUm3Xz_fbq62qRNSdilVrGIcRGUFFlwW1hprc-tklpmyMBbKiklrMsVLWzDFHIDihlFV5gglSLYkqzn3GNrfPcZOH3x0WNemwbaPmiopKOSUZgP65gG6b_vQDL8bqYyLnA1nScRMudDGGLDSx-APJpw0BT0K1ZNQPdrSVOhJqB7nXp_Te3vA8n7qn8EB-DADOOj44zHo6Dw2Dksf0HW6bP2jT7x_kOBqP3g39S88Yfy_jY6ZhjlkzKBiSmDsDp_Zl7Q</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Brahmania, Mayur, MD</creator><creator>Feld, Jordan, MD</creator><creator>Arif, Ambreen, MD</creator><creator>Janssen, Harry L A, Prof</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20160201</creationdate><title>New therapeutic agents for chronic hepatitis B</title><author>Brahmania, Mayur, MD ; Feld, Jordan, MD ; Arif, Ambreen, MD ; Janssen, Harry L A, Prof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-173f3405fb5e9469bbabb8bc622ad9ab0df36ba274db9373c0074a317d8e0d063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Genomes</topic><topic>Heparan sulfate</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Inflammation</topic><topic>Interferon</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Mutation</topic><topic>Polypeptides</topic><topic>Proteins</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brahmania, Mayur, MD</creatorcontrib><creatorcontrib>Feld, Jordan, MD</creatorcontrib><creatorcontrib>Arif, Ambreen, MD</creatorcontrib><creatorcontrib>Janssen, Harry L A, Prof</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brahmania, Mayur, MD</au><au>Feld, Jordan, MD</au><au>Arif, Ambreen, MD</au><au>Janssen, Harry L A, Prof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New therapeutic agents for chronic hepatitis B</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>16</volume><issue>2</issue><spage>e10</spage><epage>e21</epage><pages>e10-e21</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>Summary The treatment goal for chronic hepatitis B is true eradication of the hepatitis B virus, but this is rarely achieved with first-line treatment regimens because of an inability to disrupt covalently closed circular DNA and an inadequate host immune response. Therefore, new antiviral agents are needed to target various stages of the hepatitis B virus lifecycle and modulation of the immune system. This Review provides a summary of available regimens with their strengths and limitations, and highlights future therapeutic strategies to target the virus and host immune response. These new agents can hopefully lead to a finite duration of treatment, and provide a functional and durable cure for chronic hepatitis B infection.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>26795693</pmid><doi>10.1016/S1473-3099(15)00436-3</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2016-02, Vol.16 (2), p.e10-e21 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1765108112 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antiviral agents Antiviral Agents - therapeutic use Deoxyribonucleic acid DNA Genomes Heparan sulfate Hepatitis Hepatitis B Hepatitis B virus - drug effects Hepatitis B, Chronic - drug therapy Humans Immune response Immune system Infectious Disease Infectious diseases Inflammation Interferon Liver cancer Liver cirrhosis Liver diseases Mutation Polypeptides Proteins Virus Replication - drug effects |
| title | New therapeutic agents for chronic hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T15%3A37%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20therapeutic%20agents%20for%20chronic%20hepatitis%20B&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Brahmania,%20Mayur,%20MD&rft.date=2016-02-01&rft.volume=16&rft.issue=2&rft.spage=e10&rft.epage=e21&rft.pages=e10-e21&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(15)00436-3&rft_dat=%3Cproquest_cross%3E1765108112%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1762458333&rft_id=info:pmid/26795693&rft_els_id=S1473309915004363&rfr_iscdi=true |